Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBIT Margin (2018 - 2025)

Neurogene's EBIT Margin history spans 6 years, with the latest figure at 32398.75% for Q1 2025.

  • For Q1 2025, EBIT Margin fell 59356792.0% year-over-year to 32398.75%; the TTM value through Dec 2025 reached 129158.75%, up 13811808.0%, while the annual FY2024 figure was 8930.27%, N/A changed from the prior year.
  • EBIT Margin reached 32398.75% in Q1 2025 per NGNE's latest filing, up from 2176.65% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 625966.67% in Q1 2024 to a low of 2176.65% in Q2 2024.
  • Average EBIT Margin over 3 years is 272672.19%, with a median of 233449.38% recorded in 2023.
  • Peak YoY movement for EBIT Margin: soared 19146667bps in 2024, then tumbled -59356792bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 434500.0% in 2023, then plummeted by -101bps to 2176.65% in 2024, then soared by 1588bps to 32398.75% in 2025.
  • Per Business Quant, the three most recent readings for NGNE's EBIT Margin are 32398.75% (Q1 2025), 2176.65% (Q2 2024), and 625966.67% (Q1 2024).